Titlebook: Management of Chemotherapy-Induced Nausea and Vomiting; New Agents and New U Rudolph M. Navari Book 2016 Springer International Publishing

FLAK

書目名稱Management of Chemotherapy-Induced Nausea and Vomiting影響因子(影響力)




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting影響因子(影響力)學(xué)科排名




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting網(wǎng)絡(luò)公開(kāi)度




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting被引頻次




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting被引頻次學(xué)科排名




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting年度引用




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting年度引用學(xué)科排名




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting讀者反饋




書目名稱Management of Chemotherapy-Induced Nausea and Vomiting讀者反饋學(xué)科排名

祖先

http://image.papertrans.cn/m/image/622459.jpg

companion

Clinical Management of CINV,Antiemetic guidelines have been published by NCCN [1], ASCO [2], and MASCC [3]. These guidelines form the basis for the recommendations for the management of CINV. As new information and new studies emerge, the guidelines will evolve to provide the highest quality evidence-based clinical practice.

Pudendal-Nerve

建筑師

eczema

Conclusions,milar efficacy in the prevention of acute CINV for patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). These agents do not appear to have significant efficacy in the prevention of delayed CINV, and these agents compete primarily on an economic basis.

Opponent

filial

adduction

modifier